Pages that link to "Q45251847"

The following pages link to Haplotype structures of EPHX1 and their effects on the metabolism of carbamazepine-10,11-epoxide in Japanese epileptic patients. (Q45251847):

Displaying 25 items.

• Microsomal epoxide hydrolase 1 (EPHX1): Gene, structure, function, and role in human disease (Q28608628) (← links)
• Update on the Genetic Polymorphisms of Drug-Metabolizing Enzymes in Antiepileptic Drug Therapy (Q33664128) (← links)
• The role of pharmacogenetics in the metabolism of antiepileptic drugs: pharmacokinetic and therapeutic implications (Q34610817) (← links)
• Polymorphic Variants of SCN1A and EPHX1 Influence Plasma Carbamazepine Concentration, Metabolism and Pharmacoresistance in a Population of Kosovar Albanian Epileptic Patients (Q35837256) (← links)
• Association of carbamazepine major metabolism and transport pathway gene polymorphisms and pharmacokinetics in patients with epilepsy (Q36603317) (← links)
• The relationship between pharmacokinetic parameters of carbamazepine and therapeutic response in epileptic patients (Q37675543) (← links)
• Genetic polymorphism in metabolism and host defense enzymes: implications for human health risk assessment (Q37775981) (← links)
• Pharmacogenomics and epilepsy: the road ahead (Q37946957) (← links)
• Implications of pharmacogenetics for the therapeutic use of antiepileptic drugs (Q38181565) (← links)
• Effects of EPHX1 and CYP3A4 polymorphisms on carbamazepine metabolism in epileptic patients. (Q39313577) (← links)
• Pharmacogenomics in Asia: a systematic review on current trends and novel discoveries (Q39359391) (← links)
• Effects of EPHX1 and CYP3A4*22 genetic polymorphisms on carbamazepine metabolism and drug response among Tunisian epileptic patients (Q39700743) (← links)
• Association between PK/PD-involved gene polymorphisms and carbamazepine-individualized therapy. (Q41445901) (← links)
• Effects of major transporter and metabolizing enzyme gene polymorphisms on carbamazepine metabolism in Chinese patients with epilepsy (Q41704645) (← links)
• PharmGKB summary: carbamazepine pathway (Q42157342) (← links)
• Genetic profile of patients with epilepsy on first-line antiepileptic drugs and potential directions for personalized treatment (Q42985589) (← links)
• Association of ABCB1, CYP3A4, EPHX1, FAS, SCN1A, MICA, and BAG6 polymorphisms with the risk of carbamazepine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis in Chinese Han patients with epilepsy. (Q54206970) (← links)
• Association of polymorphisms in EPHX1, UGT2B7, ABCB1, ABCC2, SCN1A and SCN2A genes with carbamazepine therapy optimization. (Q55055431) (← links)
• Carbamazepine-Mediated Adverse Drug Reactions: CBZ-10,11-epoxide but Not Carbamazepine Induces the Alteration of Peptides Presented by HLA-B∗15:02 (Q57300409) (← links)
• A genome-wide association study of sodium levels and drug metabolism in an epilepsy cohort treated with carbamazepine and oxcarbazepine (Q64235675) (← links)
• The Impact of Potassium Channel Gene Polymorphisms on Antiepileptic Drug Responsiveness in Arab Patients with Epilepsy. (Q64993171) (← links)
• Defining drug disposition determinants: a pharmacogenetic-pharmacokinetic strategy (Q80997948) (← links)
• Application of TDM, pharmacogenomics and biomarkers for neurological disease pharmacotherapy: focus on antiepileptic drugs (Q88790393) (← links)
• Pharmacogenetics of antiepileptic drugs: A brief review (Q89329281) (← links)
• The increasing challenge of the possible impact of ethnicity on psychopharmacology (Q89959099) (← links)